<DOC>
	<DOCNO>NCT00781443</DOCNO>
	<brief_summary>This multicenter , randomize , double-blind , placebo-controlled study design demonstrate safety efficacy MILR1444A compare placebo reduce airway reaction inhale aeroallergen solution adult patient mild allergic asthma . The study randomize approximately 24 patient five study center . In event patient discontinuation study , additional patient may enrol discretion Sponsor .</brief_summary>
	<brief_title>A Study Evaluate MILR1444A Prevention Allergen-Induced Airway Obstruction Adults With Mild Allergic Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Airway Obstruction</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Meet criterion diagnosis allergic asthma Diagnosis asthma ≥ 6 month Currently treat intermittent shortacting inhaled βadrenergic agonist Body weight 40120 kg Normal chest Xray within 2 year screen Require daily controller medication asthma History hypersensitivity study drug drug similar chemical structure ingredient , include excipients study medication drug relate MILR1444A ( e.g. , monoclonal antibody , polyclonal gamma globulin ) Documented medical history anaphylaxis Immunotherapy currently within past 3 month prior screen Lung disease mild allergic asthma Previous treatment investigational drug within 30 day 5 halflives prior screen visit , whichever longer Pregnant lactate Significant concurrent medical illness asthma Clinically significant abnormality ECG screen visit Smoked previous 6 month history smoke 10 packyears History helminthic infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>Asthma</keyword>
</DOC>